ArticleAmerican journal of translational research2021
Zhenqing recipe relieves diabetic nephropathy through the SIK1/SREBP-1c axis in type 2 diabetic rats.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Abnormal lipid metabolism in senescent renal tubular cells in diabetic nephropathy.Cellular and molecular life sciences : CMLS · 2026Review
- Metformin Inhibits the Growth of Hypopharyngeal Squamous Cell Carcinoma of Fadu Cell and Down-Regulates LncAROD to Improve Prognosis.Anti-cancer agents in medicinal chemistry · 2026Article
- Mitochondrial metabolic reprogramming in diabetic kidney disease.Cell death & disease · 2024Review
- Identification of key regulatory genes and their working mechanisms in type 1 diabetes.BMC medical genomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalt-inducible kinase 1 (SIK1) plays an important role in lipid metabolism, which inhibits lipid synthesis by directly phosphorylating multiple serine residue sites of sterol regulatory element-binding protein 1c (SREBP-1c). This study examined potential therapeutic effect of a Chinese herbal medicine Zhenqing Recipe (ZQR) and metformin on diabetic nephropathy and investigated whether the SIK1/SREBP-1c axis is involved.
methodsThe rat model of type 2 diabetes was developed by high-sucrose plus high fat diet for one month combined with low-dose Streptozocin intraperitoneal injection for three days, after which the presence of hyperglycemia and hyperlipidemia was examined to validate the model. The diabetic rats were then randomly allocated to diabetic groups treated by either ZQR or metformin, and normal rats receiving normal diet were included as a control group. Metabolic parameters, renal function, and renal triglyceride were examined and compared between groups.
resultsAfter a treatment of 12 weeks, ZQR and metformin significantly reduced serum glucose and triglyceride, inhibited diabetic nephropathy and improved renal function. The mRNA level of SIK1 was significantly lower in the diabetic rats than that in the control group, while the expression of SREBP-1c had an opposite pattern. However, after receiving ZQR or metformin treatment, the SIK1 level in diabetic rats increased and the SREBP-1c level was downregulated. Consistent results were observed at the protein level.
conclusionThe data suggested that similar to metformin, ZQR could alleviate diabetic nephropathy through SIK1/SREBP-1c axis.
Indexed as
Identifiers
35035716PMC8748144W4206853941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.